Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altamira Therapeutics Ltd (NQ: CYTO )

0.2445 +0.0095 (+4.04%)
Streaming Delayed Price Updated: 3:58 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altamira Therapeutics Ltd

< Previous 1 2 3 4 5 6 Next >
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) jumped 52.3% to $1.3396. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors. Future... 
Via Benzinga
20 Stocks Moving in Thursday's Pre-Market Session
Gainers BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) rose 33.6% to $3.10 in pre-market trading. BiondVax reported successful closing of $9.8 million follow-on underwritten... 
Via Benzinga
45 Biggest Movers From Yesterday
Gainers Puxin Limited (NYSE: NEW) shares surged 80% to close at $0.54 on Wednesday after reporting results for the second quarter. United Time Technology Co., Ltd. (NASDAQ: UTME... 
Via Benzinga
26 Stocks Moving In Wednesday's Mid-Day Session
Gainers Puxin Limited (NYSE: NEW) jumped 100.5% to $0.6016 after reporting results for the second quarter. ShiftPixy, Inc. (NASDAQ: PIXY) climbed 38.4% to $1.55 after surging 43... 
Via Benzinga
Altamira Therapeutics Provides Update on Bentrio Program
- Bentrio™ becoming available through Amazon platform in key German market - Definite Marketing and Distribution Agreement signed for six Asian countries - Preparations for COVID-19 trial advancing -... 
From Altamira Therapeutics
Via AccessWire
Exposures COVID-19
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) rose 95.5% to $2.19 in pre-market trading after surging 43% on Tuesday. Pop Culture Group Co., Ltd (NASDAQ: CPOP) rose 24.2% to $2.87 in... 
Via Benzinga
Altamira Therapeutics Announces Randomization of First Patients in Bentrio Trial in House Dust Mite Allergy
HAMILTON, BERMUDA / ACCESSWIRE / December 16, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Announces Randomization of First Patient in Bentrio Trial in Seasonal Allergic Rhinitis
HAMILTON, BERMUDA / ACCESSWIRE / December 1, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
42 Stocks Moving In Wednesday's Mid-Day Session
Gainers Sono Group N.V. (NASDAQ: SEV) shares jumped 66% to $24.90 after the company priced its IPO at $15 per share. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares climbed... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
54 Biggest Movers From Yesterday
Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company... 
Via Benzinga
Exposures Product Safety
25 Stocks Moving in Wednesday's Pre-Market Session
Gainers 17 Education & Technology Group Inc. (NASDAQ: YQ) rose 283.5% to $3.16 in pre-market trading. 17 Education & Technology, earlier during the month, reported a $10... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Sono Group N.V. (NASDAQ: SEV) shares climbed 154.7% to close at $38.20 on Wednesday after the company priced its IPO at $15 per share. Braze, Inc. (NASDAQ: BRZE) jumped... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Altamira Therapeutics Announces Poster Presentations at AHA Scientific Sessions 2021
- Altamira's peptide-based platform for extrahepatic RNA delivery shows promising results in management of abdominal aortic aneurysm in murine disease models - siRNA polyplexes targeting NF-kB suppress... 
From Altamira Therapeutics
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Exposures Death Intellectual Property Legal
6 Top Penny Stocks to Watch Today: SNDL, CYTO, BTB, MITQ, PHUN, RLX
Today, a range of penny stocks are surging on various news items amid broader market enthusiasm and a risk-on mindset from traders. 
Via InvestorPlace
FTCH Stock: 6 Things to Know About the Deal That Has BofA Feeling Bullish About Farfetch
Farfetch (FTCH) stock is catching the eyes of traders on Friday after Bank of America praised a new partnership for the company. 
Via InvestorPlace
CYTO Stock: The Nasal Spray News Blowing Altamira Therapeutics Sky-High Today
Altamira Therapeutics (CYTO) stock is rocketing higher on Friday following the release of positive results from a nasal spray test. 
Via InvestorPlace
Exposures COVID-19
Altamira Therapeutics Reports Positive In vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Delta Variant
- Significant reduction of infectious viral titer in human nasal epithelium model with either prophylactic or therapeutic application - Results provide further confirmation for broad applicability in... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Altamira Therapeutics and Wellesta Collaborate for Marketing and Distribution of Bentrio in Six Key Asian Markets
HAMILTON, BERMUDA / ACCESSWIRE / October 25, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
44 Biggest Movers From Yesterday
Gainers Benessere Capital Acquisition Corp. (NASDAQ: BENER) shares jumped 66.5% to close at $0.4530 on Thursday. Grove, Inc. (NASDAQ: GRVI) gained 39.3% to close at $6.98 after... 
Via Benzinga
Altamira Therapeutics Receives FDA Acceptance for Bentrio 510(k) Application
HAMILTON, BERMUDA / ACCESSWIRE / October 14, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Product Safety
Altamira Therapeutics to Participate in A.G.P.'s Virtual Biotech and Specialty Pharma Conference
HAMILTON, BERMUDA / ACCESSWIRE / October 6, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA... 
From Altamira Therapeutics
Via AccessWire
Altamira Submits FDA 510(k) Premarket Notification For Bentrio
Altamira Therapeutics Ltd (NASDAQ: CYTO) has submitted a 510(k) premarket notification to the FDA for Bentrio for hay fever. Once cleared, the Company anticipates... 
Via Benzinga
Exposures Product Safety
Altamira Therapeutics Provides Update on Bentrio Program
- Building Bentrio™ brand and expanding in European markets - 510(k) premarket notification for allergy indication submitted to the U.S. Food and Drug Administration ("FDA") - Distributors signed up... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Altamira Therapeutics to Provide Business Update on Bentrio(TM) Program
HAMILTON, BERMUDA / ACCESSWIRE / September 21, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
HAMILTON, BERMUDA / ACCESSWIRE / September 9, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Provides Business Update and Reports First Half 2021 Financial Results
- Commercial launch of Bentrio™ nasal spray in first EU markets, with plans to expand to additional European and international markets in the second half of 2021 - Enrollment in Phase 2 trial of AM-125... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Altamira Therapeutics Reports Protective Effects of Bentrio(TM) Nasal Spray Against Influenza A Virus (H1N1)
- Significant reduction of viral titer in human nasal epithelium model both in prevention and treatment of influenza infection (p<0.01) - New data demonstrate protective effects in viral infections... 
From Altamira Therapeutics
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Exposures Death Intellectual Property Legal
Altamira Therapeutics Announces Launch of Website Dedicated to Bentrio(TM) Nasal Spray
HAMILTON, BERMUDA / ACCESSWIRE / August 3, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.